hydralazine has been researched along with fosinopril in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fu, J; Kim, L; Lee, T; Ritchie, ME | 1 |
| Attias, J; Breslow, JL; Brodsky, S; Coleman, R; Hayek, T; Keidar, S; Smith, J | 1 |
| Bi, WF; Chang, NC; Lai, ZY; Lin, MS; Shih, CM; Wang, TC | 1 |
| An, SJ; Choi, JH; Choi, KD; Kim, HJ; Kim, JS; Lee, JE | 1 |
1 review(s) available for hydralazine and fosinopril
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for hydralazine and fosinopril
| Article | Year |
|---|---|
Fosinopril improves left ventricular diastolic function in young mildly hypertensive patients without hypertrophy.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Echocardiography, Doppler; Female; Fosinopril; Humans; Hydralazine; Hydrochlorothiazide; Hypertension; Male; Reference Values; Time Factors; Ventricular Function, Left | 2002 |
5 other study(ies) available for hydralazine and fosinopril
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Characterization of MAP kinase and PKC isoform and effect of ACE inhibition in hypertrophy in vivo.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Cardiomegaly; Enzyme Activation; Fosinopril; Hydralazine; Hypertension; Isoenzymes; Mitogen-Activated Protein Kinases; Nuclear Proteins; Phosphoproteins; Protein Kinase C; Rats; Rats, Sprague-Dawley; Response Elements; Transfection | 1999 |
The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Drug Administration Schedule; Fosinopril; Hydralazine; Hypertension; Lipid Peroxidation; Lipoproteins, LDL; Losartan; Mice; Mice, Transgenic; Oxidation-Reduction; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2 | 1999 |
Simultaneous posterior ischemic optic neuropathy, cerebral border zone infarction, and spinal cord infarction after correction of malignant hypertension.
Topics: Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Brain; Brain Stem Infarctions; Cerebral Infarction; Disease Progression; Female; Fosinopril; Humans; Hydralazine; Hypertension, Malignant; Hypotension; Iatrogenic Disease; Magnetic Resonance Imaging; Nifedipine; Optic Neuropathy, Ischemic; Paraparesis; Spinal Cord; Spinal Cord Ischemia; Tetrazoles; Urinary Incontinence; Vision, Low | 2008 |